Healthcare IT
MMIT interviewed more than 300 pharma and biotech leaders to learn what keeps them up at night—and what gets them going in the morning. Read on for the survey findings and expert analysis.
MMIT helps pharma companies harness the power of real world data to better understand the patient journey.
One of the first steps in your therapy’s commercialization journey should be to identify high-value HCPs who can help guide valuation, messaging and more.
Our Zitter Insights Panel uses research to illuminate the complexities of market access.
Industry Leading Insights
MMIT offers a range of publications for pharma, payers and providers covering news, strategy and insights across the spectrum. Our in-house journalism division AIS Health provides objective news and analysis of industry trends while RJ Health provides a comprehensive look at industry updates as they apply to medically covered drug reimbursement processes.
In the complex healthcare analytics landscape, understanding the nuances of open and closed claims is critical for researchers and analysts. Open and closed claims each offer unique insights into the patient journey.
Our first post in this series discussed how early market access research, conducted in the 12-18 months before launch, helps pharma companies identify differentiators and establish accurate expectations.
Before physicians prescribe a new therapy, they need to trust that it is the most effective and appropriate treatment for an individual patient.
According to our 2024 State of Patient Access survey, 81% of pharma companies are launching their market access planning much earlier than they did five years ago.
For the past year, Medicaid has been the predominant topic of conversation for those who monitor insurance market share shifts
Vertical integration between payers, PBMs, specialty pharmacies, and providers has grown in the last decade, with more negotiating power concentrated among a handful of major players.
Get the latest from MMIT’s leading subject matter experts, receiving the latest posts right to your inbox. Top-quality thought leadership 100% free.
August 23, 2024
At Asembia's AXS24 Summit, MMIT's Dinesh Kabaleeswaran and The Dedham Group's Jen Klarer presented on the results of the 2024 State of Patient Access survey. In this article, Specialty Pharmacy Continuum shares key points from their presentation.
July 23, 2024
The House Committee on Oversight and Accountability held a hearing on the business practices of the three largest PBMs. Fierce Healthcare tapped MMIT’s Andrew Rouff for commentary on the investigation into whether PBMs are responsible for inflating drug prices.
July 9, 2024
Patient access issues across the value chain are prompting manufacturers to invest in early-stage market access planning using real-world data. MMIT's Dinesh Kabaleeswaran and The Dedham Group's Jen Klarer explain these industry shifts.
June 2, 2024
Eli Lilly's drug will be marketed under the brand name Kisunla for treating adults with early symptomatic Alzheimer’s disease. MM&M asked MMIT's Chief Clinical Officer Jayne Hornung for commentary on this exciting news.
May 13, 2024
At a Pharmaceutical Executive roundtable event on the state of marketing in the pharmaceutical industry, MMIT's Jay Shah and Skipta's Glen Saunders shared their thoughts on digital strategies, the use of AI, and the impact of med-legal regulations on marketing campaigns.
April 2024
This research paper explores how payers’ familiarity with AI tools and explores the likelihood of AI implementation to reduce administrative burden across managed care and government organizations.
March 20, 2024
Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner for overcoming barriers to patient access, has announced the finalists of its ninth Specialty Pharmacy Patient Choice Awards.
February 14, 2024
This review of current benefit designs uses MMIT’s data on commercial plans’ use of copay accumulators and maximizers.
January 20, 2024
The movement of care from high-cost, post-acute sites to lower-cost freestanding and non-acute sites has accelerated. This research paper explores the impact of payer site-of-care preferences across payers, oncologists and physicians.
January 18, 2024
The increased popularity of anti-obesity medications is raising questions about inequities in patient access, due to both shortages and limited payer coverage policies.
January 17, 2024
The application of AI will expand into managed care organizations in the near future. For payers and PBMs, AI tools can be useful for tasks including claims processing, prior authorization review, and data retrieval.
January 14, 2024
Biosimilars offer substantial promise for a new era of accessibility and affordability for patients, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential.
January 2, 2024
By blending claims, lab, and EHR data with payer coverage and clinical pathway data, pharma companies can gain full visibility into what’s happening in the market before they launch.
December 4, 2023
Patient Access Analytics received the Gold Award for Technology Solutions in Healthcare.
November 29, 2023
Life sciences companies will face several challenges in the new year, from more pressure on pipelines to the ongoing consequences of regulatory changes. Norstella experts share their predictions.
October 9, 2023
Many oncology manufacturers assume that a therapy’s inclusion on clinical pathways is more important than its coverage profile, but this isn’t always true.
September 15, 2023
Insulin price caps and list price reductions are a huge step forward for patient access. But what will these changes mean for health plans?
September 13, 2023
Rebate leakage drains millions in revenue from pharma companies every year. To ensure contract compliance, manufacturers can implement these five steps.